Navigation Links
Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer

Cold Spring Harbor, NY Gregory J. Hannon, Ph.D., Cold Spring Harbor Laboratory (CSHL) professor and Howard Hughes Medical Institute (HHMI) investigator, along with two other young investigators will be the recipients of the Memorial Sloan-Kettering Cancer Centers (MSKCC) 2007 Paul Marks Prize for Cancer Research.

The prize, named after Paul A. Marks, Ph.D., President Emeritus of MSKCC, recognizes significant contributions to the basic understanding and treatment of cancer by scientists no more than 45 years old at the time they are nominated. The winners were selected by a committee chaired by Jeffrey M. Friedman, M.D., Ph.D., a professor at The Rockefeller University. Each receives a medal and share a cash award of $150,000.

It is important to show appreciation for the work of younger scientists while they are still in the early stages of their careers, said Dr. Friedman. The Paul Marks Prize pays tribute to the man for whom it was named by honoring some of the most promising researchers of the next generation.

Dr. Hannon is a leader in the relatively new field of RNA interference (RNAi), a naturally occurring mechanism for regulating the expression of genes (controlling which genes are turned on and turned off in cells). In the laboratory, it is used as a tool to study the function of specific genes, and its being investigated as a therapeutic approach for treating many different diseases, including cancer.

Greg Hannons discoveries have had a broad impact on research related to the field of small RNA biology, said Bruce Stillman, Ph.D., CSHL President. As a leader in the RNAi field, Gregs work has resulted in the identification of a process that can manipulate gene expression, leading to a greater understanding of gene function, and identifying potential therapeutic drug targets.

Dr. Hannon earned his Ph.D. degree in molecular biology from Case Western Reserve University.

The Paul Marks Prize was established in 2001 and is awarded biennially. This years winners Hannon, Angelika Amon, Ph.D., of the Massachusetts Institute of Technology (MIT) and the Howard Hughes Medical Institute (HHMI), and Todd R. Golub, M.D., of the Dana-Farber Cancer Institute, the Broad Institute of Harvard and MIT, and the HHMI will speak about their work at a public symposium held at Memorial Sloan-Kettering Cancer Center on December 6, 2007.

Each investigator we are honoring is already a leader in his or her respective field, said Harold Varmus, M.D., MSKCC President. These scientists have made major contributions to the biological understanding of cancer, shedding light on what causes cancer and offering promising solutions that may someday provide benefits to patients everywhere.

In addition to Dr. Friedman, other members of the selection committee were Joan S. Brugge, PhD, of the Department of Cell Biology at Harvard Medical School; Titia de Lange, PhD, of The Rockefeller University; Stephen J. Elledge, PhD, of the Department of Biochemistry at Baylor College of Medicine; Stephen P. Goff, PhD, of the Department of Microbiology at Columbia University; Alan Hall, PhD, of the Cell Biology Program in the Sloan-Kettering Institute; Scott W. Lowe, PhD, of the Cold Spring Harbor Cancer Center; and William G. Kaelin Jr., MD, of the Dana-Farber Cancer Institute.


Contact: Jim Bono
Cold Spring Harbor Laboratory

Related biology news :

1. Neuronal traffic jam marks early Alzheimers disease
2. New gene scanning technology marks a major advance in disease research
3. Novel molecular signature marks DNA of embryonic stem cells
4. Scientists map key landmarks in human genome
5. LEGO-Like building blocks to halt cell growth wins Hebrew University prize
6. Comments, experts and background on the 2006 Nobel Prize in chemistry
7. New research says winning a Nobel Prize adds nearly 2 years to your lifespan
8. Australian wins prestigious prize in biodiversity informatics
9. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
10. Zebrafish may hold key to understanding human nerve cell development
11. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
Post Your Comments:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology: